ZKZuzanna Zofia Kamińska

Zuzanna Zofia Kamińska

*This is an algorithmically generated author record based on publicly available information.

Zuzanna Zofia Kamińska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk Stratification and Contemporary Therapeutic Strategies in Pediatric Pulmonary Hypertension: A Narrative Review

    by Agnieszka Zielińska, Zuzanna Zofia Kamińska, Gabriela Senda, Michał Gorlo

    Background: Pediatric pulmonary hypertension (PH) is a rare, heterogeneous disease marked by progressive pulmonary vascular resistance and right ventricular pressure overload, with significant morbidity and mortality. Targeted pharmacotherapy has advanced, yet management is complicated by diverse causes, developmental differences from adult disease, and limited pediatric evidence. Risk stratification is now the foundation for individualized treatment. Aim: This review summarizes evidence on risk stratification and therapy in pediatric PH, focusing on prognostic tools and targeted treatments supporting personalized management. Material and methods: We conducted a narrative review of PubMed/MEDLINE literature from January 2020 to mid-2026, using pediatric- and PH-specific search terms, supplemented by manual screening of reference lists. Priority was given to guidelines, registry-based and multicenter cohort studies, and recent work on multidimensional risk assessment, cardiac imaging, invasive hemodynamics, biomarkers, pharmacotherapy, and advanced interventions. Results: Management has shifted from a disease-oriented toward an individualized, risk-guided approach. Reliable prognosis depends on integrating clinical evaluation, echocardiography, cardiac MRI, invasive hemodynamics, and biomarkers, rather than any single parameter. Dynamic risk stratification enables earlier detection of progression and timely escalation. Pharmacological management increasingly relies on combination therapy targeting nitric oxide, endothelin, and prostacyclin pathways, while emerging agents and interventions expand options for high-risk patients. Conclusions: Risk stratification is the cornerstone of pediatric PH management. Individualized strategies based on continuous assessment enable earlier intervention, optimized treatment, and appropriate selection of advanced therapies. Further multicenter studies are needed to validate risk models and strengthen treatment guidance.

  • Open Access

    Pulmonary Hypertension: Pathogenesis, Diagnosis and Management - Current Concepts and Future Perspectives

    by Aleksandra Jakimowicz, Małgorzata Blecharczyk, Martyna Mrozek, Martyna Pacanowska-Trawnicka, Igor Zydlewski, Agnieszka Zielińska, Zuzanna Zofia Kamińska, Aleksandra Malcher

    Background: Pulmonary hypertension (PH) is a complex and heterogeneous conditioncharacterized by elevated pulmonary arterial pressure, increased pulmonary vascularresistance, and progressive right ventricular failure.Objective: This review aims to summarize current knowledge on the pathogenesis, clinicalpresentation, diagnostic approaches, and treatment of PH, with particular emphasis onpulmonary arterial hypertension (PAH).Methods: A narrative review of the literature was conducted, including recent clinicalstudies, review articles, and current guidelines addressing the pathophysiology, diagnosis, andmanagement of PH.Results: Key mechanisms underlying PH include endothelial dysfunction, vascularremodeling, and dysregulation of the prostacyclin, nitric oxide, and endothelin pathways.Diagnostic strategies are based on non-invasive assessment and right heart catheterization.Current therapies improve exercise capacity and quality of life but do not reverse vascularremodeling.Conclusions: Despite significant advances, PH remains associated with poor prognosis.Future research focusing on molecular mechanisms and novel therapeutic targets may enablemore effective and personalized treatment strategies

  • Open Access

    Orforglipron as a Small-Molecule GLP-1 Receptor Agonist: A New Era of Incretin-Based Oral Therapy?

    by Małgorzata Blecharczyk, Aleksandra Jakimowicz, Zuzanna Zofia Kamińska, Aleksandra Malcher, Martyna Mrozek, Martyna Pacanowska-Trawnicka, Agnieszka Zielińska, Igor Zydlewski

    Introduction: Facing the increasing number of people suffering from obesity, overweight and weight-related comorbidities, the development of medications that support weight loss is crucial. The currently available therapies based on glucagon-like peptide receptor 1 agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 RAs allow for weight loss of 8-21% [1]. However, a significant factor reducing treatment adherence is subcutaneous route of administation by injection, as well ass - in the case of oral semaglutide – restrictive dosing requirements: the drug need to be taken at least 30 minutes before the first meal, beverage, or other oral medication in the morning and with no more than 120 ml of plain water [2]. Aim of the study: The purpose of this study is to review the safety and tolerance of orforglipron and to compare it with oral semaglutide based on ACHIEVE-3 clinical trail. Material and Methods: Review and analysis of randomised clinical trials available on PubMed. We excluded phase 1 trials in analysis of patients with obesity without diabetes mellitus and patients with DM2. Notably, main clinical trials focusing on orforglipron were funded or supported by Eli Lilly and Company. Conclusions: Orforglipron is definitely promising as a small-molecule GLP-1 receptor agonist. The therapy is effective in body weight reduction and results in a significant, dose-dependent reduction in HbA1c levels. With significant effect on weight loss, cardiometabolic parameters and improvement in glycemic profile, it can be used in combination with a reduced-calorie diet and increased physical activity in adults, as a weight-loss therapy or in patient with type 2 diabetes. However, all of the studies published so far on the innovative molecule of orforglipron were based on limited number of patients, therefore long-term safety, tolerance in a larger population and general long-term impact of orforglipron on health needs extensive studies.

  • Open Access

    Effects of Female Reproductive Hormones on Performance, Injury Risk, and Recovery: Implications for Evidence-Based Practice

    by Aleksandra Malcher, Zuzanna Zofia Kamińska, Agnieszka Zielińska, Igor Zydlewski, Aleksandra Jakimowicz, Martyna Pacanowska-Trawnicka, Martyna Mrozek, Małgorzata Blecharczyk

    Background. Women's participation in sport has grown substantially, yet female athletes remain underrepresented in sport science research, with much of the existing evidence derived from male populations. Fluctuations of estrogen and progesterone across the menstrual cycle, together with widespread use of hormonal contraceptives, are increasingly recognised as factors that may influence athletic outcomes. Aim. To synthesise current evidence on the effects of female reproductive hormones on athletic performance, injury risk, and recovery, and to translate it into practical, individualised recommendations for coaches, practitioners, and athletes. Methods. PubMed was searched for systematic reviews, meta-analyses, and original studies on the menstrual cycle, hormonal contraceptives, and athletic outcomes. Results. Group-level effects of menstrual cycle phase on objective performance outcomes such as strength, power, and endurance are generally small and inconsistent. Evidence linking cycle phase to anterior cruciate ligament injury risk is suggestive but limited by methodological heterogeneity, whereas hormonal contraceptive use does not appear to be protective against musculoskeletal injuries. Outcomes related to recovery appear more sensitive to hormonal context than objective performance measures, with recent evidence converging on menstrual symptom burden as a predictor of disturbed recovery in female athletes. Conclusions. Female reproductive hormones influence multiple physiological systems relevant to sport, but their effects on athletic outcomes are predominantly individual rather than uniform. The strongest evidence-based approach for supporting female athletes combines individualised, symptom-led monitoring with established principles of training periodisation, injury prevention, and athlete education. Progress in this field will depend on longitudinal research with biochemical phase verification and a focus on individual response patterns.

  • Open Access

    Comparison of effectiveness and safety of TAVI and SAVR in treatment of severe, symptomatic aortic stenosis – a literature review

    by Igor Zydlewski, Małgorzata Blecharczyk, Martyna Mrozek, Martyna Pacanowska-Trawnicka, Aleksandra Jakimowicz, Agnieszka Zielińska, Zuzanna Kamińska, Aleksandra Malcher

    Introduction Aortic stenosis is the most common acquired, valvular heart disease among adults in developed countries. It causes exercise tolerance deterioration, left ventricle hypertrophy and leads to heart failure or even death. Available treatment methods for severe, symptomatic aortic stenosis include Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (SAVR). While it has been proven that TAVI is superior to SAVR in patients with high surgical risk, there is still little data considering patients with lower risk profile. Aim of study The aim of this study is to assess the differences between TAVI procedure and the Surgical Aortic Valve Replacement in terms of their efficacy and safety in patients with severe aortic stenosis and low to intermediate surgical risk. This article is based on the analysis of randomised controlled trials published between years 2021 and 2026. Conclusion TAVI is a safe and effective alternative to SAVR in patients with severe, symptomatic aortic stenosis and low to intermediate surgical risk. It is associated with a lower incidence of major bleeding, stroke and myocardial infarction while presenting comparable or lower mortality in short to medium term. It is, however, correlated with more frequent vascular complications and pacemaker implantations. There is a need for further research on a larger group of patients, with a longer follow-up time in order to assess optimal guidelines for TAVI and SAVR in patients with this risk profile.

  • Open Access

    Maternal and Environmental Risk Factors for Congenital Heart Diseases in Offspring: A Review Article

    by Agnieszka Zielińska, Zuzanna Zofia Kamińska, Małgorzata Blecharczyk, Martyna Mrozek, Igor Zydlewski, Martyna Pacanowska-Trawnicka, Aleksandra Jakimowicz, Aleksandra Malcher

    Background. Congenital heart diseases (CHDs) are the most common congenital anomalies and a leading cause of infant morbidity and mortality. Although genetic factors play an important role, many cases remain unexplained, highlighting the contribution of maternal and environmental exposures. Aim. This review aims to provide a comprehensive and up-to-date synthesis of non-genetic maternal risk factors associated with CHDs in offspring. Material and methods. A literature review was conducted using PubMed, NCBI and Google Scholar, including studies published between 2010 and 2025. Systematic reviews, meta-analyses, cohort and case-control studies evaluating maternal and environmental exposures were analyzed. Results. Evidence indicates that maternal diabetes and obesity are key risk factors, with clear dose-response relationships. Additional contributors include smoking (active and passive), alcohol consumption, infections, fever, psychological stress and environmental pollutants. Protective effects of folic acid and multivitamin supplementation were also observed. Interaction effects between environmental exposures and parental behaviors further increase CHD risk. Conclusions. CHD etiology is multifactorial, involving modifiable maternal and environmental factors. Identification and reduction of these exposures, particularly during early pregnancy, are essential for prevention. Further prospective and mechanistic studies are needed to clarify causal pathways and improve risk reduction strategies.

  • Open Access

    Probiotics in Pediatric Atopic Dermatitis: Prevention and Therapeutic Potential – A Literature Review

    by Zuzanna Zofia Kamińska, Agnieszka Zielińska, Martyna Mrozek, Małgorzata Blecharczyk, Igor Zydlewski, Aleksandra Malcher, Martyna Pacanowska-Trawnicka, Aleksandra Jakimowicz

    Introduction. Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterised by impaired epidermal barrier and immune dysregulation. It is becoming increasingly prevalent in the pediatric population. Recent research highlights the role of the gut-skin axis and suggests that the intestinal microbiota may influence the development and course of inflammatory skin diseases, including AD. Aim of the study. This review aims to evaluate the current evidence regarding the use of probiotics in the treatment and prevention of atopic dermatitis in the pediatric population. Material and methods. A literature search was conducted using the PubMed database to identify relevant studies discussing the role of probiotics in treatment and prevention of atopic dermatitis in children. Meta-analyses, randomized controlled trials and systematic reviews were included. Results. Included studies suggest that probiotic supplementation may reduce the severity of atopic dermatitis, as measured by the SCORAD index, particularly in moderate-to-severe AD, and when administered for longer durations. Moreover, they may be useful in prevention of AD in high-risk infants, especially during the prenatal period. However, results vary depending on study design, probiotic strain, population and duration of supplementation. Conclusion. Probiotics may be a promising new strategy as an adjunct therapy in the treatment and prevention of pediatric atopic dermatitis. Nevertheless, further research, mostly well-designed randomized controlled trials are needed in order to determine optimal strains, dosage and duration of treatment.

  • Open Access

    From Balance to Rupture: Vaginal Microbiome in pPROM

    by Martyna Mrozek, Małgorzata Blecharczyk, Zuzanna Zofia Kamińska, Agnieszka Zielińska, Igor Zydlewski, Martyna Pacanowska-Trawnicka, Aleksandra Jakimowicz, Aleksandra Malcher

    PROM and its preterm form, pPROM, are major contributors to preterm birth and remain closely associated with serious maternal and neonatal complications. Growing evidence suggests that disruption of vaginal microbial homeostasis mayis closely linked to the pathogenesis of pPROM. In particular, the loss of protective Lactobacillus crispatus, accompanied by a shift toward Lactobacillus iners, anaerobic bacteria, and increased microbial diversity, appears to destabilize the vaginal ecosystem, promote local inflammation, activate matrix metalloproteinases, and ultimately compromise the structural integrity of the fetal membranes. Current empirical antibiotic therapy for pPROM does not account for interindividual variability in the vaginal microbiota and may paradoxically aggravate dysbiosis. In response to these limitations, emerging therapeutic strategies are increasingly focused on microbiota-targeted interventions, including personalized probiotic therapies, immunological and biological approaches, and vaginal microbiota transplantation. In addition, specific microbial signatures may serve as potential biomarkers of pPROM, thereby opening new avenues for personalized prevention and treatment. Although further prospective studies are required to validate the safety and efficacy of these emerging therapies, their potential already represents a promising direction for the future of modern perinatal medicine.

  • Open Access

    How Does Caffeine Enhance Athletic Performance? A Literature Review of Its Effects, Mechanisms of Action, Safety, Side Effects, and Sport- and Sex-Based Differences.

    by Martyna Pacanowska-Trawnicka, Małgorzata Blecharczyk, Igor Zydlewski, Martyna Mrozek, Aleksandra Jakimowicz, Agnieszka Zielińska, Zuzanna Kamińska, Aleksandra Malcher

    Introduction: Caffeine is a methylxanthine compound naturally found in coffee beans, tea leaves, and cocoa. It is among the most widely consumed psychoactive substances worldwide. Its primary mechanism of action involves antagonism of adenosine receptors within the central nervous system, resulting in reduced perception of fatigue and enhanced alertness. Caffeine’s effects on the peripheral nervous system include increased intracellular calcium release and inhibition of phosphodiesterase activity, thereby enhancing muscle contractility and promoting utilization of energy substrates [1]. The metabolic effects of caffeine encompass multiple biochemical pathways [8]. Although caffeine exerts a multifactorial effect on aerobic performance its use should be carefully considered in the context of potential adverse effects [12]. Evidence derived from studies conducted in diverse athletic populations suggests that caffeine supplementation may represent an effective strategy for optimizing performance while preserving long-term athlete health.Aim of the study :The aim of this study is to systematically analyze available literature regarding the effects of caffeine, its mechanisms of action, safety profile, adverse effects, and variability in response according to sport discipline and sex.Material and Methods: Review and analysis of randomized clinical trials and clinical trials from 2010 to 2025 available on PubMed and Google Scholar.Conclusions: The findings indicate that caffeine may serve as an effective ergogenic aid across a wide range of sports disciplines, provided that it is administered within safe dosage ranges tailored to individual needs—taking into account the specific characteristics of the discipline, athlete-related factors and individual tolerance [2]. Furthermore, current evidence indicates comparable magnitude of benefits in both female and male athletes across various disciplines [5], highlighting the broad applicability of caffeine as an ergogenic aid.